Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Exclusion Criteria

• •1. Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years. Stage I malignant tumor after radical treatment for at least 3 years, except those considered by investigators to have small possibility of recurrence. Patients with radically treated carcinoma in situ (non-infiltrating) and skin cancer other than malignant melanoma can be enrolled;
• •2. Having received antitumor therapy (including chemotherapy, hormone therapy, biotherapy, immunotherapy or traditional Chinese medicine for antitumor indication) within 3 weeks prior to the start of study treatment, or having received treatment with small molecular tyrosine kinase inhibitors (e.g., EGFR-TKI) within 2 weeks prior to the start of study treatment;
• •3. Received extensive radiotherapy within 4 weeks of treatment
• •4. Received close distance radiotherapy within 60 days
• •5. Major surgery within 4 weeks of treatment
• •6. Taken strong CYP3A4 inducer within 2 weeks
• •7. Not recovered from past anti-tumor treatment toxicity
• •8. Active HIV infection
• •9. Active Hepatitis B or C infection